Ra Pharmaceuticals(RARX)

47.995 0.00 0.0%

今开:0.0昨收:47.995
最高:0.0 最低:0.0
涨停价:0.0跌停价:0.0
总市值:2.271549356E9

Ra Pharmaceuticals的最新讨论

旭日待东升2019-10-11 11:53

昨日美国医药行业大事:
$Ra Pharmaceuticals(RARX)$ 果然是好标的,之前持续上涨,刚刚回调,就被UCB作价21亿收购了。昨日涨幅100%
$OncoSec医疗(ONCS)$ China Grand Pharma 投资2500万,收购44.2%的股份,还将可能以超4.5美元的价格收购余下股份。
$Reata制药(RETA)$ StiffL 给予买...查看全文

美港探案2019-10-10 23:53

$达美航空(DAL)$ 跌逾3%,尽管Q3盈利超预期;$Ra Pharmaceuticals(RARX)$ 暴涨逾100%,UCB将以21亿美元收购前者;PG&E大跌30%,因破产法官允许Elliot提出重组计划;3B家居大涨22%,任命前塔吉特高管为新任CEO;$如涵(RUHN)$ 招股书被指误导投资人,在美一个月遭逾10宗集体诉讼。查看全文

美股马甲2019-10-10 23:00

$Ra Pharmaceuticals(RARX)$ 能不能把XBI重新拉起来……查看全文

chuminhua2019-10-10 21:11

$Ra Pharmaceuticals(RARX)$ $UCB(UCBJY)$ 10/10,UCB宣布以每股48美元,总计21亿美元现金收购Ra Pharma。前一天Ra Pharma的收盘价为22.70美元。Ra的C5抑制剂zilucoplan正在开展治疗重症肌无力(MG)的III期临床,该产品有望与Alexion的Soliris竞争。查看全文

英为财情Investing2019-10-10 20:43

$达美航空(DAL)$ 跌逾3%,尽管Q3盈利超预期;$Ra Pharmaceuticals(RARX)$ 暴涨逾100%,UCB将以21亿美元收购前者;PG&E大跌30%,因破产法官允许Elliot提出重组计划;3B家居大涨22%,任命前塔吉特高管为新任CEO;$如涵(RUHN)$ 招股书被指误导投资人,在美一个月遭逾10宗集体诉讼。查看全文

淘沙见金2019-10-10 18:42

$Ra Pharmaceuticals(RARX)$ EU pharma quite active in H2 so far on M&As
July: Boehringer Ingelheim / Amal Tx, Zambon / Breath Tx
Aug: Bayer / BlueRock Tx
Sept: Lundbeck / Alder Biopharma, SOBI / Dova Pharma
Oct: UCB / Ra Pharma
延续了最近欧洲药企来抄底的主查看全文

牛唐2019-03-16 14:58

$Akari Therapeutics(AKTX)$ FDA同意coversin在HSCT-TMA适应症的关键阶段的实验设计,引发了翻倍的增长,如果后续数据好的话,未来市值有望跟相$Ra Pharmaceuticals(RARX)$$奥麦罗制药(OMER)$ 相比查看全文

Apellis Pharmaceutical:补体分子C3抑制剂的价值

淘沙见金2017-11-09 11:56

(个人笔记,欢迎讨论)
Apellis Pharmaceutical $Apellis Pharmaceuticals, Inc.(APLS)$ 是一家生物制药临床研发公司,头号在研药物APL2是补体分子C3抑制剂,用于治疗各种自身免疫性疾病如年龄相关性黄斑变性(AMD),PNH,自身免疫性溶血性贫血(Autoimmune hemolytic anemia,AIHA)和年龄相关...查看全文

Ra Pharmaceuticals的公告

$Ra Pharmaceuticals(RARX)$ 内部交易: 2019-07-15,Chief Medical Officer,Farzaneh-Far Ramin ,期权,10595普通股, $5.60

$Ra Pharmaceuticals(RARX)$ 8-K - Current report Filed: 2019-07-16 AccNo: 0001104659-19-040451 Size: 27 KBItem 1.01: Entry into a Material Definitive Agreement 网页链接

$Ra Pharmaceuticals(RARX)$ 内部交易: 2019-06-21,See Remarks,Ricardo Alonso ,卖出,2857普通股, $23.72

$Ra Pharmaceuticals(RARX)$ 内部交易: 2019-06-17,Chief Medical Officer,Farzaneh-Far Ramin ,卖出,10595普通股, $21.84

$Ra Pharmaceuticals(RARX)$ 内部交易: 2019-06-17,Chief Medical Officer,Farzaneh-Far Ramin ,期权,10595普通股, $5.60

$Ra Pharmaceuticals(RARX)$ 内部交易: 2019-06-18,Chief Scientific Officer,Read Simon ,卖出,10000普通股, $22.25

$Ra Pharmaceuticals(RARX)$ 内部交易: 2019-06-18,Chief Scientific Officer,Read Simon ,期权,10000普通股, $2.87

$Ra Pharmaceuticals(RARX)$ 8-K - Current report Filed: 2019-06-12 AccNo: 0001104659-19-035100 Size: 37 KBItem 5.07: Submission of Matters to a Vote of Security Holders 网页链接

$Ra Pharmaceuticals(RARX)$ S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers Filed: 2019-05-09 AccNo: 0001047469-19-002981 Size: 766 KB 网页链接

$Ra Pharmaceuticals(RARX)$ 8-K - Current report Filed: 2019-05-09 AccNo: 0001104659-19-028232 Size: 308 KBItem 1.01: Entry into a Material Definitive AgreementItem 9.01: Financial Statements and Exhibits 网页链接

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19